USA - NASDAQ:CARL - US14280C1053 - Common Stock
The current stock price of CARL is 14.685 USD. In the past month the price increased by 9.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.99 | 238.75B | ||
ISRG | INTUITIVE SURGICAL INC | 54.98 | 158.65B | ||
SYK | STRYKER CORP | 29.49 | 144.86B | ||
BSX | BOSTON SCIENTIFIC CORP | 34.17 | 143.30B | ||
MDT | MEDTRONIC PLC | 17.2 | 122.00B | ||
BDX | BECTON DICKINSON AND CO | 13.05 | 53.39B | ||
IDXX | IDEXX LABORATORIES INC | 53.58 | 51.48B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.79 | 43.43B | ||
RMD | RESMED INC | 28.76 | 40.21B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 34.03B | ||
DXCM | DEXCOM INC | 40.89 | 27.26B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.64 | 27.07B |
Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. The company is headquartered in Carlsbad, California. The company went IPO on 2025-07-23. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights intended to improve the digital surgical planning process. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
CARLSMED INC
1800 Aston Ave., Suite 100
Carlsbad CALIFORNIA US
Employees: 0
Phone: 17607661923
The current stock price of CARL is 14.685 USD. The price increased by 3.78% in the last trading session.
The exchange symbol of CARLSMED INC is CARL and it is listed on the Nasdaq exchange.
CARL stock is listed on the Nasdaq exchange.
11 analysts have analysed CARL and the average price target is 18.77 USD. This implies a price increase of 27.8% is expected in the next year compared to the current price of 14.685. Check the CARLSMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CARLSMED INC (CARL) has a market capitalization of 390.33M USD. This makes CARL a Small Cap stock.
CARLSMED INC (CARL) currently has 0 employees.
CARLSMED INC (CARL) has a support level at 13.35 and a resistance level at 14.8. Check the full technical report for a detailed analysis of CARL support and resistance levels.
The Revenue of CARLSMED INC (CARL) is expected to decline by -12.4% in the next year. Check the estimates tab for more information on the CARL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CARL does not pay a dividend.
CARLSMED INC (CARL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).
The outstanding short interest for CARLSMED INC (CARL) is 3.3% of its float. Check the ownership tab for more information on the CARL short interest.
ChartMill assigns a technical rating of 4 / 10 to CARL.
ChartMill assigns a fundamental rating of 2 / 10 to CARL. The financial health of CARL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CARL reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS decreased by -31.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -85.93% | ||
ROE | -154.73% | ||
Debt/Equity | 0.48 |
11 analysts have analysed CARL and the average price target is 18.77 USD. This implies a price increase of 27.8% is expected in the next year compared to the current price of 14.685.